CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

FIIs Favourite: Caplin Steriles Secures US FDA Approval, FIIs Stake Rises to 4.86 per cent
Abhishek Wani
/ Categories: Trending, Mindshare

FIIs Favourite: Caplin Steriles Secures US FDA Approval, FIIs Stake Rises to 4.86 per cent

Caplin Point Laboratories has demonstrated robust financial performance in recent quarters. The company reported revenue of Rs 1,523 crore for Q3 FY25, which is equivalent to its full-year revenue in FY23.

Caplin Point Laboratories has made headlines once again as its subsidiary, Caplin Steriles, secured the final approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) concerning Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution. Despite this positive development, shares of Caplin Point Laboratories were trading 2.42 per cent lower at 2:50 PM on February 27, 2025.

Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is a widely used ophthalmic medication that helps lower intraocular pressure in patients suffering from glaucoma or ocular hypertension. The drug is a generic therapeutic equivalent of AbbVie Inc.'s reference product, COMBIGAN. According to estimates from IQVIATM, this medication generated approximately USD 242 million in sales in the United States during the 12 months ending December 2024. The approval marks a crucial milestone for Caplin Steriles, allowing the company to further strengthen its presence in the regulated markets.

Caplin Point Laboratories has demonstrated robust financial performance in recent quarters. The company reported revenue of Rs 1,523 crore for Q3 FY25, which is equivalent to its full-year revenue in FY23. Additionally, the Profit Before Tax (PBT) for FY24-25 has already exceeded Rs 500 crore, compared to Rs 451 crore recorded in FY22-23. The company's Profit After Tax (PAT) has also increased to Rs 396 crore, up from Rs 377 crore in the previous fiscal year. Caplin Point’s gross margin for the latest quarter stands at an impressive 60.4 per cent, with EBITDA margins at 36.9 per cent and PAT margins at 26.7 per cent. Notably, operating expenses have remained controlled at 25 per cent to 26 per cent of revenue, even as the company doubled its employee strength over the last four years.

On the strategic front, Caplin Point Laboratories continues to expand its footprint in Latin America, targeting Mexico and Chile in the short term while planning to enter Colombia and Brazil in the mid-to-long term. The company has also initiated front-end operations in the U.S. market, following the model of successful injectable companies that have established a direct presence in the region. In addition, Caplin Point has identified two manufacturing facilities in Mexico to support the production of oral solids, ointments, and suppositories for contract manufacturing opportunities. The company also aims to develop 80-85 Active Pharmaceutical Ingredients (APIs) for captive consumption, with excess production capacity being utilized in China.

DSIJ’s ‘Flash News Investment' weekly Newsletter recommends profit-making ideas for you based on fundamental and technical analysis. If this interests you, do download the service details here.

Caplin Point Laboratories is a fast-growing pharmaceutical company with a unique business model focused on emerging markets in Latin America and Africa. The company operates state-of-the-art manufacturing facilities that cater to a wide range of finished dosage forms. With a market capitalisation of over Rs 14,639 crore, Caplin Point has been a preferred choice for institutional investors. The stock, however, has witnessed a 23 per cent correction on a year-to-date basis in 2025. According to the December 2024 shareholding pattern, Foreign Institutional Investors (FIIs) have increased their stake in the company to 4.86 per cent, indicating strong confidence in its future prospects.

Disclaimer: This article is for informational purposes only and should not be considered investment advice.

 

Previous Article Sensex & Nifty End Flat, Midcap & Smallcap Indices Down Upto 1.7 Per Cent
Next Article Bandhan Bank Surges as RBI Eases Risk-Weight Norms for Loans to NBFCs
Print
112 Rate this article:
4.7
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR